Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 65 | 2024 | 5836 | 5.720 |
Why?
|
Carcinoma, Merkel Cell | 9 | 2024 | 328 | 4.260 |
Why?
|
Melanoma | 40 | 2024 | 5695 | 3.690 |
Why?
|
Immunohistochemistry | 64 | 2024 | 11035 | 3.000 |
Why?
|
Sweat Gland Neoplasms | 9 | 2013 | 109 | 2.820 |
Why?
|
Skin | 20 | 2024 | 4482 | 2.740 |
Why?
|
Polyomavirus Infections | 4 | 2023 | 193 | 2.660 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 6 | 2017 | 26 | 2.400 |
Why?
|
Uveal Neoplasms | 4 | 2024 | 343 | 2.220 |
Why?
|
Ki-67 Antigen | 11 | 2024 | 628 | 2.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 15 | 2023 | 2054 | 1.750 |
Why?
|
Ubiquitin Thiolesterase | 5 | 2024 | 455 | 1.690 |
Why?
|
Tumor Virus Infections | 4 | 2023 | 438 | 1.670 |
Why?
|
Nevus, Pigmented | 8 | 2015 | 222 | 1.380 |
Why?
|
Vulvar Neoplasms | 4 | 2024 | 265 | 1.330 |
Why?
|
Carcinoma, Squamous Cell | 14 | 2023 | 4047 | 1.280 |
Why?
|
Carcinoma, Basal Cell | 4 | 2020 | 565 | 1.150 |
Why?
|
Drug Eruptions | 4 | 2017 | 334 | 1.130 |
Why?
|
Carcinoma | 7 | 2013 | 2313 | 1.100 |
Why?
|
Apocrine Glands | 3 | 2012 | 31 | 1.100 |
Why?
|
Tumor Suppressor Proteins | 6 | 2024 | 2793 | 1.080 |
Why?
|
Penile Neoplasms | 3 | 2024 | 158 | 1.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 1105 | 1.030 |
Why?
|
Sebaceous Gland Neoplasms | 3 | 2013 | 40 | 1.020 |
Why?
|
Diagnosis, Differential | 38 | 2021 | 12975 | 0.930 |
Why?
|
Facial Neoplasms | 3 | 2012 | 126 | 0.910 |
Why?
|
Eccrine Porocarcinoma | 3 | 2013 | 18 | 0.910 |
Why?
|
Skin Diseases, Genetic | 1 | 2024 | 49 | 0.870 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2021 | 120 | 0.860 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2024 | 115 | 0.840 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 4 | 2022 | 41 | 0.840 |
Why?
|
Biopsy | 25 | 2024 | 6768 | 0.800 |
Why?
|
Alopecia | 4 | 2019 | 415 | 0.780 |
Why?
|
Hair Follicle | 4 | 2015 | 220 | 0.780 |
Why?
|
Pilomatrixoma | 2 | 2013 | 24 | 0.770 |
Why?
|
Syphilis | 3 | 2019 | 243 | 0.770 |
Why?
|
Adenoma, Sweat Gland | 2 | 2013 | 16 | 0.760 |
Why?
|
Eccrine Glands | 2 | 2012 | 52 | 0.750 |
Why?
|
GATA3 Transcription Factor | 3 | 2017 | 163 | 0.730 |
Why?
|
Merkel Cells | 1 | 2020 | 24 | 0.710 |
Why?
|
Aged, 80 and over | 46 | 2024 | 59493 | 0.710 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 2020 | 64 | 0.700 |
Why?
|
Panniculitis | 1 | 2020 | 45 | 0.700 |
Why?
|
Carcinoma, Skin Appendage | 2 | 2011 | 5 | 0.690 |
Why?
|
Vaginal Neoplasms | 1 | 2021 | 105 | 0.690 |
Why?
|
Skin Diseases, Vesiculobullous | 4 | 2013 | 82 | 0.680 |
Why?
|
Mutation | 20 | 2024 | 30208 | 0.650 |
Why?
|
Humans | 190 | 2024 | 766000 | 0.650 |
Why?
|
Middle Aged | 89 | 2024 | 223025 | 0.650 |
Why?
|
Carcinoma in Situ | 4 | 2019 | 777 | 0.640 |
Why?
|
Precancerous Conditions | 3 | 2023 | 975 | 0.630 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2023 | 343 | 0.630 |
Why?
|
Vulvar Diseases | 2 | 2014 | 64 | 0.630 |
Why?
|
PTEN Phosphohydrolase | 2 | 2024 | 1117 | 0.620 |
Why?
|
Carcinosarcoma | 2 | 2024 | 108 | 0.610 |
Why?
|
DNA Mutational Analysis | 10 | 2023 | 4112 | 0.610 |
Why?
|
Oral Ulcer | 2 | 2019 | 95 | 0.610 |
Why?
|
Keratin-15 | 4 | 2010 | 22 | 0.610 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 5 | 2014 | 67 | 0.610 |
Why?
|
Behcet Syndrome | 2 | 2019 | 86 | 0.600 |
Why?
|
Intermediate Filament Proteins | 5 | 2012 | 261 | 0.600 |
Why?
|
Antigens, Neoplasm | 4 | 2024 | 1996 | 0.600 |
Why?
|
Skin Diseases | 6 | 2015 | 1083 | 0.590 |
Why?
|
Membrane Proteins | 6 | 2021 | 7850 | 0.560 |
Why?
|
Adenocarcinoma | 9 | 2017 | 6361 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2017 | 82 | 0.540 |
Why?
|
Mucous Membrane | 1 | 2020 | 658 | 0.540 |
Why?
|
Aged | 60 | 2024 | 171161 | 0.540 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2019 | 243 | 0.540 |
Why?
|
Male | 102 | 2024 | 363855 | 0.540 |
Why?
|
GTP Phosphohydrolases | 2 | 2019 | 524 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-kit | 7 | 2021 | 723 | 0.500 |
Why?
|
Myelodysplastic Syndromes | 2 | 2024 | 1404 | 0.490 |
Why?
|
Melanocytes | 7 | 2023 | 504 | 0.490 |
Why?
|
Arthritis | 1 | 2020 | 676 | 0.480 |
Why?
|
Female | 104 | 2024 | 396158 | 0.480 |
Why?
|
Molecular Targeted Therapy | 3 | 2017 | 2825 | 0.480 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2017 | 614 | 0.480 |
Why?
|
Cadherins | 3 | 2023 | 900 | 0.470 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2016 | 218 | 0.470 |
Why?
|
Kaplan-Meier Estimate | 6 | 2021 | 6506 | 0.470 |
Why?
|
Cell Nucleus | 3 | 2020 | 2864 | 0.470 |
Why?
|
Antibodies, Monoclonal | 7 | 2014 | 9237 | 0.470 |
Why?
|
Adult | 75 | 2024 | 223106 | 0.470 |
Why?
|
von Hippel-Lindau Disease | 4 | 2003 | 154 | 0.460 |
Why?
|
Skin Diseases, Papulosquamous | 2 | 2006 | 17 | 0.460 |
Why?
|
Predictive Value of Tests | 15 | 2024 | 15401 | 0.450 |
Why?
|
Pituitary Gland, Anterior | 1 | 2014 | 142 | 0.450 |
Why?
|
In Situ Hybridization | 3 | 2017 | 1885 | 0.450 |
Why?
|
Nerve Tissue Proteins | 9 | 2022 | 4399 | 0.450 |
Why?
|
Vulva | 2 | 2013 | 84 | 0.450 |
Why?
|
Avitaminosis | 1 | 2014 | 35 | 0.450 |
Why?
|
Adrenal Cortex | 1 | 2014 | 134 | 0.440 |
Why?
|
Prognosis | 16 | 2024 | 29904 | 0.440 |
Why?
|
Pancreatitis | 1 | 2020 | 1086 | 0.440 |
Why?
|
Cicatrix | 2 | 2010 | 797 | 0.430 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 2 | 2007 | 23 | 0.430 |
Why?
|
Eye Diseases | 1 | 2019 | 660 | 0.430 |
Why?
|
Nevus, Blue | 2 | 2011 | 43 | 0.430 |
Why?
|
Lip | 1 | 2015 | 196 | 0.430 |
Why?
|
Nevus | 2 | 2005 | 204 | 0.420 |
Why?
|
Paget Disease, Extramammary | 1 | 2013 | 50 | 0.420 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2013 | 21 | 0.420 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2021 | 8613 | 0.420 |
Why?
|
Lymphatic Metastasis | 6 | 2024 | 2890 | 0.420 |
Why?
|
Neoplasm Proteins | 6 | 2021 | 3594 | 0.420 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1814 | 0.420 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2023 | 2425 | 0.410 |
Why?
|
Pemphigus | 1 | 2013 | 107 | 0.410 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2021 | 4649 | 0.410 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 1088 | 0.410 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11202 | 0.410 |
Why?
|
Dermatitis | 1 | 2014 | 201 | 0.400 |
Why?
|
Rocky Mountain Spotted Fever | 1 | 2012 | 19 | 0.400 |
Why?
|
Head and Neck Neoplasms | 4 | 2024 | 2926 | 0.400 |
Why?
|
Bile Ducts, Extrahepatic | 2 | 2002 | 50 | 0.400 |
Why?
|
Proto-Oncogene Proteins | 4 | 2023 | 4520 | 0.390 |
Why?
|
Exanthema | 5 | 2019 | 503 | 0.390 |
Why?
|
Tuberculosis, Cutaneous | 2 | 2018 | 17 | 0.390 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2024 | 2945 | 0.380 |
Why?
|
Poland | 2 | 2023 | 197 | 0.380 |
Why?
|
Calciphylaxis | 1 | 2013 | 129 | 0.370 |
Why?
|
Vulvitis | 1 | 2010 | 8 | 0.360 |
Why?
|
Up-Regulation | 1 | 2020 | 4133 | 0.360 |
Why?
|
Laryngeal Neoplasms | 2 | 2005 | 514 | 0.360 |
Why?
|
Vision Disorders | 2 | 2019 | 1087 | 0.360 |
Why?
|
Rhabdomyolysis | 1 | 2012 | 150 | 0.360 |
Why?
|
Papillomaviridae | 1 | 2017 | 1137 | 0.360 |
Why?
|
Carcinoma, Small Cell | 2 | 2004 | 419 | 0.360 |
Why?
|
Acrospiroma | 1 | 2010 | 10 | 0.360 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2022 | 2158 | 0.350 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4886 | 0.350 |
Why?
|
Ulcer | 3 | 2020 | 202 | 0.350 |
Why?
|
Scalp Dermatoses | 2 | 2019 | 44 | 0.340 |
Why?
|
Immunoenzyme Techniques | 10 | 2016 | 1695 | 0.340 |
Why?
|
Skin Ulcer | 2 | 2021 | 131 | 0.340 |
Why?
|
Mixed Tumor, Malignant | 1 | 2009 | 16 | 0.330 |
Why?
|
Hemangioblastoma | 2 | 2014 | 62 | 0.330 |
Why?
|
Hamartoma | 1 | 2011 | 235 | 0.320 |
Why?
|
Stem Cells | 3 | 2011 | 3537 | 0.310 |
Why?
|
Phosphoproteins | 2 | 2019 | 2445 | 0.310 |
Why?
|
Pituitary Neoplasms | 2 | 2014 | 1322 | 0.310 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 373 | 0.310 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1609 | 0.310 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2017 | 2510 | 0.310 |
Why?
|
RNA, Viral | 1 | 2017 | 2868 | 0.310 |
Why?
|
Receptors, Nerve Growth Factor | 3 | 2021 | 199 | 0.300 |
Why?
|
Lupus Erythematosus, Cutaneous | 2 | 2006 | 75 | 0.300 |
Why?
|
Dermatofibrosarcoma | 3 | 2007 | 49 | 0.300 |
Why?
|
Histones | 3 | 2009 | 2591 | 0.300 |
Why?
|
Urticaria | 3 | 2022 | 151 | 0.300 |
Why?
|
Herpesvirus 6, Human | 2 | 1999 | 96 | 0.300 |
Why?
|
Treponema pallidum | 2 | 2006 | 48 | 0.300 |
Why?
|
Papillomavirus Infections | 2 | 2017 | 1637 | 0.300 |
Why?
|
Syndrome | 3 | 2024 | 3270 | 0.290 |
Why?
|
Keratins | 6 | 2012 | 496 | 0.290 |
Why?
|
Antigens, CD34 | 3 | 2009 | 656 | 0.290 |
Why?
|
Cell Proliferation | 6 | 2024 | 10431 | 0.290 |
Why?
|
Immunoglobulin A | 1 | 2011 | 992 | 0.290 |
Why?
|
Folliculitis | 2 | 2019 | 25 | 0.290 |
Why?
|
GTP-Binding Protein alpha Subunits | 2 | 2023 | 103 | 0.290 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2023 | 148 | 0.280 |
Why?
|
Hydroxychloroquine | 2 | 2021 | 429 | 0.280 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2023 | 752 | 0.270 |
Why?
|
Ear, External | 2 | 2004 | 165 | 0.270 |
Why?
|
Synaptophysin | 2 | 2023 | 137 | 0.270 |
Why?
|
Granular Cell Tumor | 1 | 2007 | 46 | 0.270 |
Why?
|
Syphilis, Cutaneous | 1 | 2006 | 6 | 0.270 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2024 | 733 | 0.270 |
Why?
|
Inhibins | 3 | 2003 | 210 | 0.270 |
Why?
|
Follicular Cyst | 1 | 2006 | 2 | 0.270 |
Why?
|
Polymerase Chain Reaction | 8 | 2017 | 6057 | 0.260 |
Why?
|
Schistosoma haematobium | 1 | 2006 | 14 | 0.260 |
Why?
|
Young Adult | 18 | 2021 | 59857 | 0.260 |
Why?
|
Receptor, erbB-2 | 5 | 2013 | 2593 | 0.260 |
Why?
|
Schistosomiasis haematobia | 1 | 2006 | 16 | 0.260 |
Why?
|
Neoplasms, Basal Cell | 1 | 2006 | 30 | 0.260 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2006 | 54 | 0.260 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5791 | 0.260 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1765 | 0.250 |
Why?
|
Immunosuppressive Agents | 3 | 2014 | 4213 | 0.250 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2023 | 3664 | 0.250 |
Why?
|
Epidermal Cyst | 1 | 2006 | 63 | 0.250 |
Why?
|
Scalp | 2 | 2024 | 389 | 0.250 |
Why?
|
Dermatomycoses | 1 | 2005 | 45 | 0.240 |
Why?
|
Neoplasm Invasiveness | 7 | 2017 | 3604 | 0.240 |
Why?
|
Retrospective Studies | 22 | 2024 | 81542 | 0.240 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 904 | 0.240 |
Why?
|
Carcinoma, Verrucous | 1 | 2005 | 26 | 0.240 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2005 | 121 | 0.240 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2005 | 61 | 0.240 |
Why?
|
SOXE Transcription Factors | 2 | 2023 | 74 | 0.240 |
Why?
|
Ascomycota | 1 | 2005 | 82 | 0.230 |
Why?
|
Ampulla of Vater | 1 | 2005 | 150 | 0.230 |
Why?
|
Caspase 3 | 1 | 2007 | 731 | 0.230 |
Why?
|
Miliaria | 1 | 2004 | 6 | 0.230 |
Why?
|
Tuberculosis, Miliary | 1 | 2004 | 13 | 0.230 |
Why?
|
Survival Analysis | 5 | 2020 | 10089 | 0.230 |
Why?
|
Ichthyosiform Erythroderma, Congenital | 1 | 2004 | 7 | 0.230 |
Why?
|
Chondrodysplasia Punctata | 1 | 2004 | 10 | 0.230 |
Why?
|
Antineoplastic Agents | 4 | 2018 | 13634 | 0.230 |
Why?
|
Keratin-6 | 2 | 2014 | 15 | 0.230 |
Why?
|
Dysplastic Nevus Syndrome | 3 | 2014 | 59 | 0.230 |
Why?
|
DNA, Neoplasm | 3 | 2011 | 1739 | 0.230 |
Why?
|
Histiocytosis, Langerhans-Cell | 2 | 2007 | 169 | 0.230 |
Why?
|
Keratin-5 | 2 | 2014 | 43 | 0.230 |
Why?
|
Necrosis | 3 | 2023 | 1614 | 0.230 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3111 | 0.220 |
Why?
|
Testicular Diseases | 1 | 2004 | 72 | 0.220 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2024 | 85 | 0.220 |
Why?
|
Immunocompromised Host | 4 | 2020 | 865 | 0.220 |
Why?
|
Trisomy | 2 | 2010 | 260 | 0.220 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2004 | 590 | 0.220 |
Why?
|
Giant Cell Tumors | 2 | 2007 | 89 | 0.220 |
Why?
|
Matrix Attachment Region Binding Proteins | 1 | 2023 | 48 | 0.220 |
Why?
|
Carcinoid Tumor | 2 | 2002 | 225 | 0.220 |
Why?
|
Esophageal Neoplasms | 2 | 2005 | 1659 | 0.210 |
Why?
|
Cecal Neoplasms | 1 | 2003 | 27 | 0.210 |
Why?
|
Granuloma, Plasma Cell | 1 | 2004 | 80 | 0.210 |
Why?
|
Endolymphatic Sac | 1 | 2003 | 49 | 0.210 |
Why?
|
Gene Fusion | 2 | 2024 | 357 | 0.210 |
Why?
|
Biological Products | 1 | 2012 | 947 | 0.210 |
Why?
|
Ear Neoplasms | 1 | 2003 | 118 | 0.210 |
Why?
|
Transcription Factors | 6 | 2024 | 12128 | 0.210 |
Why?
|
Ear Diseases | 1 | 2004 | 181 | 0.210 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 1351 | 0.200 |
Why?
|
Biopsy, Needle | 5 | 2018 | 1613 | 0.200 |
Why?
|
Forkhead Transcription Factors | 2 | 2021 | 1623 | 0.200 |
Why?
|
Intranuclear Inclusion Bodies | 1 | 2022 | 34 | 0.200 |
Why?
|
Breast Neoplasms | 6 | 2024 | 21072 | 0.200 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2006 | 391 | 0.200 |
Why?
|
Ossification, Heterotopic | 1 | 2004 | 239 | 0.200 |
Why?
|
Glioma | 2 | 2015 | 3492 | 0.190 |
Why?
|
Receptor, IGF Type 2 | 1 | 2021 | 35 | 0.190 |
Why?
|
Chromosomes, Human, X | 1 | 2004 | 319 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-ret | 4 | 2016 | 228 | 0.190 |
Why?
|
Glucocorticoids | 4 | 2019 | 2156 | 0.190 |
Why?
|
Adrenocortical Carcinoma | 1 | 2002 | 88 | 0.190 |
Why?
|
Leiomyosarcoma | 2 | 2003 | 425 | 0.190 |
Why?
|
Carcinoma, Islet Cell | 1 | 2001 | 21 | 0.190 |
Why?
|
Loss of Heterozygosity | 3 | 2016 | 663 | 0.190 |
Why?
|
Sensitivity and Specificity | 7 | 2014 | 14644 | 0.190 |
Why?
|
Silicone Gels | 1 | 2021 | 39 | 0.190 |
Why?
|
Gene Amplification | 2 | 2010 | 1088 | 0.190 |
Why?
|
Neoplasms | 5 | 2022 | 22336 | 0.190 |
Why?
|
Membrane Glycoproteins | 2 | 2010 | 3692 | 0.190 |
Why?
|
Adolescent | 20 | 2021 | 88808 | 0.180 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 41 | 0.180 |
Why?
|
Buttocks | 1 | 2021 | 111 | 0.180 |
Why?
|
Adenoma, Oxyphilic | 1 | 2002 | 150 | 0.180 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2002 | 161 | 0.180 |
Why?
|
Thiolester Hydrolases | 1 | 2001 | 91 | 0.180 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2003 | 195 | 0.180 |
Why?
|
Lymph Nodes | 6 | 2023 | 3457 | 0.180 |
Why?
|
Telomerase | 2 | 2016 | 749 | 0.180 |
Why?
|
Medical Tourism | 1 | 2021 | 51 | 0.180 |
Why?
|
Herpesviridae Infections | 2 | 1999 | 268 | 0.180 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 159 | 0.180 |
Why?
|
Lichen Planus | 1 | 2021 | 70 | 0.180 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2004 | 663 | 0.170 |
Why?
|
Mucins | 1 | 2003 | 567 | 0.170 |
Why?
|
Soft Tissue Neoplasms | 2 | 2007 | 1163 | 0.170 |
Why?
|
Herpesvirus 2, Human | 1 | 2021 | 191 | 0.170 |
Why?
|
Dermis | 1 | 2021 | 204 | 0.170 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2023 | 385 | 0.170 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2001 | 169 | 0.170 |
Why?
|
Carrier Proteins | 1 | 2013 | 4910 | 0.170 |
Why?
|
Claudins | 1 | 2020 | 118 | 0.170 |
Why?
|
Genes, erbB-2 | 1 | 2000 | 161 | 0.170 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2020 | 220 | 0.170 |
Why?
|
Honey | 1 | 2019 | 12 | 0.170 |
Why?
|
Iritis | 1 | 2019 | 15 | 0.160 |
Why?
|
Antirheumatic Agents | 1 | 2009 | 1380 | 0.160 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2003 | 488 | 0.160 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2024 | 453 | 0.160 |
Why?
|
Amino Acid Substitution | 2 | 2014 | 1742 | 0.160 |
Why?
|
Stromal Cells | 2 | 2021 | 1332 | 0.160 |
Why?
|
Taiwan | 1 | 2020 | 521 | 0.160 |
Why?
|
Lichen Sclerosus et Atrophicus | 1 | 2019 | 26 | 0.160 |
Why?
|
Epitopes | 3 | 2021 | 2523 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2021 | 791 | 0.160 |
Why?
|
Rhabdomyosarcoma | 1 | 2002 | 354 | 0.160 |
Why?
|
Staphylococcal Skin Infections | 1 | 2019 | 77 | 0.160 |
Why?
|
Tissue Fixation | 2 | 2017 | 245 | 0.160 |
Why?
|
Sex Chromosome Aberrations | 1 | 1999 | 116 | 0.160 |
Why?
|
Herpesviridae | 1 | 1999 | 104 | 0.150 |
Why?
|
Parvovirus B19, Human | 1 | 1998 | 42 | 0.150 |
Why?
|
Clinical Chemistry Tests | 1 | 1998 | 59 | 0.150 |
Why?
|
Hedgehog Proteins | 1 | 2023 | 771 | 0.150 |
Why?
|
Scleritis | 1 | 2019 | 96 | 0.150 |
Why?
|
Pigmentation | 1 | 2019 | 143 | 0.150 |
Why?
|
Mesenteric Arteries | 1 | 1998 | 177 | 0.150 |
Why?
|
Herpes Simplex | 1 | 2021 | 470 | 0.150 |
Why?
|
Hospitals, General | 2 | 2013 | 803 | 0.150 |
Why?
|
Kidney Diseases | 2 | 2019 | 2100 | 0.150 |
Why?
|
Vascular Neoplasms | 1 | 2019 | 167 | 0.150 |
Why?
|
Salivary Gland Neoplasms | 1 | 2001 | 306 | 0.140 |
Why?
|
Anetoderma | 1 | 2017 | 1 | 0.140 |
Why?
|
Lung Neoplasms | 5 | 2017 | 13482 | 0.140 |
Why?
|
beta Catenin | 2 | 2020 | 1047 | 0.140 |
Why?
|
DNA Probes, HPV | 1 | 2017 | 21 | 0.140 |
Why?
|
Fundus Oculi | 1 | 2019 | 543 | 0.140 |
Why?
|
Sulfasalazine | 1 | 2017 | 85 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 3 | 2003 | 3186 | 0.140 |
Why?
|
Carcinoma, Papillary | 1 | 2002 | 786 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2003 | 731 | 0.140 |
Why?
|
Antibodies, Anticardiolipin | 1 | 2017 | 62 | 0.140 |
Why?
|
RNA Probes | 1 | 2017 | 110 | 0.140 |
Why?
|
Radiography, Abdominal | 1 | 2020 | 543 | 0.140 |
Why?
|
Pathology, Clinical | 2 | 2012 | 374 | 0.140 |
Why?
|
Fixatives | 1 | 2017 | 90 | 0.140 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12061 | 0.140 |
Why?
|
Herpesvirus 4, Human | 2 | 2002 | 1077 | 0.140 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 696 | 0.140 |
Why?
|
Death, Sudden | 1 | 1999 | 301 | 0.140 |
Why?
|
Blood Donors | 1 | 1999 | 344 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2002 | 624 | 0.140 |
Why?
|
S100 Proteins | 3 | 2002 | 214 | 0.140 |
Why?
|
Fetal Death | 1 | 1999 | 434 | 0.140 |
Why?
|
Cytodiagnosis | 2 | 2016 | 450 | 0.140 |
Why?
|
Mucinosis, Follicular | 1 | 2016 | 8 | 0.140 |
Why?
|
Carcinoembryonic Antigen | 2 | 2012 | 336 | 0.140 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 1056 | 0.130 |
Why?
|
Automation, Laboratory | 1 | 2017 | 102 | 0.130 |
Why?
|
Bone Marrow Diseases | 1 | 1998 | 234 | 0.130 |
Why?
|
Dermatology | 3 | 2012 | 905 | 0.130 |
Why?
|
Blood | 1 | 1999 | 597 | 0.130 |
Why?
|
Albumins | 1 | 1999 | 578 | 0.130 |
Why?
|
Fluorescent Antibody Technique, Direct | 2 | 2018 | 65 | 0.130 |
Why?
|
Thyroid Neoplasms | 2 | 2024 | 2355 | 0.130 |
Why?
|
Mutation, Missense | 3 | 2014 | 2590 | 0.130 |
Why?
|
Adaptive Immunity | 1 | 2021 | 733 | 0.130 |
Why?
|
Genes, p16 | 1 | 2016 | 157 | 0.130 |
Why?
|
Mongolian Spot | 1 | 2015 | 3 | 0.130 |
Why?
|
Serum Albumin | 1 | 1999 | 674 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12530 | 0.130 |
Why?
|
Paraffin Embedding | 1 | 2017 | 302 | 0.130 |
Why?
|
Herpesvirus 1, Human | 1 | 2021 | 743 | 0.130 |
Why?
|
Gangliosidosis, GM1 | 1 | 2015 | 11 | 0.130 |
Why?
|
ras Proteins | 2 | 2011 | 1054 | 0.130 |
Why?
|
Facial Dermatoses | 1 | 2016 | 87 | 0.130 |
Why?
|
Mesoderm | 1 | 1999 | 679 | 0.120 |
Why?
|
Hypertriglyceridemia | 1 | 1998 | 292 | 0.120 |
Why?
|
Kidney Neoplasms | 2 | 2003 | 4282 | 0.120 |
Why?
|
Formaldehyde | 1 | 2017 | 360 | 0.120 |
Why?
|
Nephrotic Syndrome | 1 | 1999 | 380 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 1998 | 458 | 0.120 |
Why?
|
Albuminuria | 1 | 1999 | 659 | 0.120 |
Why?
|
Embolism, Cholesterol | 1 | 2015 | 32 | 0.120 |
Why?
|
Frontal Lobe | 1 | 2022 | 1408 | 0.120 |
Why?
|
X Chromosome | 1 | 1999 | 819 | 0.120 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 452 | 0.120 |
Why?
|
Calcinosis | 1 | 2004 | 1475 | 0.120 |
Why?
|
Axonemal Dyneins | 1 | 2014 | 25 | 0.120 |
Why?
|
Immunodominant Epitopes | 1 | 2016 | 244 | 0.120 |
Why?
|
Central Nervous System Neoplasms | 1 | 2003 | 918 | 0.120 |
Why?
|
Colonic Neoplasms | 2 | 2005 | 2532 | 0.120 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1621 | 0.120 |
Why?
|
Sweet Syndrome | 2 | 2012 | 56 | 0.120 |
Why?
|
Genital Diseases, Male | 1 | 2015 | 84 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2024 | 2838 | 0.120 |
Why?
|
Proto-Oncogenes | 1 | 2015 | 320 | 0.120 |
Why?
|
Neurofibromin 1 | 1 | 2016 | 190 | 0.120 |
Why?
|
Fibroma | 2 | 2007 | 197 | 0.110 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2016 | 308 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3546 | 0.110 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2001 | 1086 | 0.110 |
Why?
|
Abdominal Pain | 1 | 2020 | 1069 | 0.110 |
Why?
|
Ascorbic Acid Deficiency | 1 | 2014 | 26 | 0.110 |
Why?
|
Cytomegalovirus | 1 | 1998 | 753 | 0.110 |
Why?
|
Substance Abuse, Intravenous | 1 | 1998 | 527 | 0.110 |
Why?
|
Pancreas | 1 | 2020 | 1699 | 0.110 |
Why?
|
Lasers | 1 | 2018 | 951 | 0.110 |
Why?
|
Anthraquinones | 1 | 2013 | 41 | 0.110 |
Why?
|
Cocaine | 1 | 1998 | 944 | 0.110 |
Why?
|
Vitamin A Deficiency | 1 | 2014 | 88 | 0.110 |
Why?
|
Spectrum Analysis, Raman | 1 | 2015 | 250 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 997 | 0.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 1434 | 0.110 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
Actins | 1 | 2020 | 2060 | 0.110 |
Why?
|
Keratin-17 | 1 | 2013 | 26 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 303 | 0.100 |
Why?
|
Fluorouracil | 1 | 2018 | 1648 | 0.100 |
Why?
|
Mohs Surgery | 1 | 2015 | 217 | 0.100 |
Why?
|
Child | 12 | 2016 | 80567 | 0.100 |
Why?
|
Spinal Cord Neoplasms | 1 | 2014 | 258 | 0.100 |
Why?
|
Receptors, Androgen | 2 | 2013 | 1088 | 0.100 |
Why?
|
Adenoma | 1 | 2003 | 2155 | 0.100 |
Why?
|
Cheek | 1 | 2012 | 65 | 0.100 |
Why?
|
Intestine, Small | 1 | 1998 | 1216 | 0.100 |
Why?
|
Laminin | 1 | 2014 | 404 | 0.100 |
Why?
|
Antibody Specificity | 1 | 2014 | 1061 | 0.100 |
Why?
|
Lymphoma | 1 | 2021 | 1897 | 0.100 |
Why?
|
Hair Color | 1 | 2012 | 131 | 0.100 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 108 | 0.100 |
Why?
|
Cholesterol, HDL | 1 | 1998 | 1811 | 0.100 |
Why?
|
Immunoglobulin M | 1 | 2017 | 1527 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2012 | 2878 | 0.100 |
Why?
|
Case-Control Studies | 3 | 2020 | 22231 | 0.100 |
Why?
|
Cisplatin | 1 | 2018 | 1654 | 0.100 |
Why?
|
Mutant Proteins | 1 | 2013 | 487 | 0.090 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 349 | 0.090 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2011 | 35 | 0.090 |
Why?
|
Fasciitis, Necrotizing | 1 | 2012 | 79 | 0.090 |
Why?
|
Abnormalities, Multiple | 1 | 1999 | 1424 | 0.090 |
Why?
|
Gastrointestinal Agents | 1 | 2016 | 511 | 0.090 |
Why?
|
Chromogranins | 2 | 2002 | 159 | 0.090 |
Why?
|
Risk Assessment | 4 | 2024 | 24272 | 0.090 |
Why?
|
Infant | 8 | 2016 | 36424 | 0.090 |
Why?
|
Peripheral Nerves | 1 | 2015 | 493 | 0.090 |
Why?
|
Craniopharyngioma | 1 | 2014 | 276 | 0.090 |
Why?
|
Headache | 1 | 2019 | 1259 | 0.090 |
Why?
|
Massachusetts | 3 | 2013 | 8882 | 0.090 |
Why?
|
Polymorphism, Genetic | 3 | 2016 | 4249 | 0.090 |
Why?
|
Arthritis, Reactive | 1 | 2010 | 19 | 0.090 |
Why?
|
Citalopram | 1 | 2013 | 402 | 0.090 |
Why?
|
Staining and Labeling | 2 | 2013 | 1072 | 0.090 |
Why?
|
Coloring Agents | 1 | 2013 | 563 | 0.090 |
Why?
|
Pyoderma Gangrenosum | 1 | 2012 | 84 | 0.090 |
Why?
|
Skin Pigmentation | 1 | 2012 | 278 | 0.090 |
Why?
|
Cilia | 1 | 2014 | 498 | 0.090 |
Why?
|
Microscopy | 1 | 2015 | 900 | 0.090 |
Why?
|
Gallbladder Neoplasms | 2 | 2002 | 190 | 0.090 |
Why?
|
Chromosome Aberrations | 2 | 2010 | 1775 | 0.090 |
Why?
|
Linear Models | 1 | 2020 | 5872 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39233 | 0.080 |
Why?
|
Survival Rate | 1 | 2024 | 12821 | 0.080 |
Why?
|
Cerebellar Neoplasms | 1 | 2014 | 570 | 0.080 |
Why?
|
Sequence Analysis, DNA | 4 | 2015 | 4779 | 0.080 |
Why?
|
Ischemia | 1 | 1998 | 1904 | 0.080 |
Why?
|
Sex Factors | 2 | 2021 | 10611 | 0.080 |
Why?
|
Erythema | 2 | 2018 | 261 | 0.080 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 580 | 0.080 |
Why?
|
Pathology, Surgical | 1 | 2010 | 146 | 0.080 |
Why?
|
Reproducibility of Results | 6 | 2017 | 20135 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 667 | 0.080 |
Why?
|
Blister | 1 | 2009 | 88 | 0.080 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 955 | 0.080 |
Why?
|
Neurofibroma | 1 | 2009 | 95 | 0.080 |
Why?
|
Deglutition Disorders | 1 | 2015 | 640 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2015 | 668 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1152 | 0.080 |
Why?
|
DNA, Viral | 3 | 2021 | 2200 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9378 | 0.080 |
Why?
|
Tissue Array Analysis | 2 | 2023 | 545 | 0.080 |
Why?
|
Microscopy, Electron | 2 | 2002 | 2543 | 0.080 |
Why?
|
Pregnancy Complications | 2 | 2017 | 2970 | 0.080 |
Why?
|
Genes, ras | 1 | 2011 | 656 | 0.080 |
Why?
|
Disease Progression | 4 | 2023 | 13613 | 0.080 |
Why?
|
Child, Preschool | 7 | 2016 | 42509 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 3431 | 0.080 |
Why?
|
Cell Differentiation | 2 | 2020 | 11642 | 0.080 |
Why?
|
Subcutaneous Tissue | 2 | 2012 | 131 | 0.070 |
Why?
|
Apolipoproteins D | 1 | 2007 | 14 | 0.070 |
Why?
|
Time Factors | 4 | 2024 | 40100 | 0.070 |
Why?
|
Monophenol Monooxygenase | 2 | 2012 | 72 | 0.070 |
Why?
|
Lymph Node Excision | 1 | 2014 | 1262 | 0.070 |
Why?
|
Fatal Outcome | 3 | 2014 | 1836 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2271 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2012 | 1100 | 0.070 |
Why?
|
HIV Infections | 3 | 2006 | 17535 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2014 | 949 | 0.070 |
Why?
|
Psoriasis | 2 | 2005 | 922 | 0.070 |
Why?
|
Trans-Activators | 2 | 2010 | 2849 | 0.070 |
Why?
|
Evaluation Studies as Topic | 2 | 2000 | 1607 | 0.070 |
Why?
|
Mitosis | 2 | 2015 | 1175 | 0.070 |
Why?
|
Age Factors | 2 | 2021 | 18382 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6840 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4783 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1885 | 0.070 |
Why?
|
Cohort Studies | 5 | 2019 | 41675 | 0.070 |
Why?
|
Xanthomatosis | 1 | 2006 | 32 | 0.070 |
Why?
|
Sex Distribution | 1 | 2011 | 2269 | 0.070 |
Why?
|
Keratin-7 | 2 | 2002 | 55 | 0.060 |
Why?
|
Argyria | 1 | 2005 | 2 | 0.060 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2013 | 958 | 0.060 |
Why?
|
Brain Neoplasms | 3 | 2015 | 9064 | 0.060 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2005 | 47 | 0.060 |
Why?
|
Age Distribution | 1 | 2011 | 2865 | 0.060 |
Why?
|
Axilla | 2 | 2014 | 619 | 0.060 |
Why?
|
Itraconazole | 1 | 2005 | 43 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2021 | 65199 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2115 | 0.060 |
Why?
|
Antibodies, Antinuclear | 1 | 2006 | 340 | 0.060 |
Why?
|
Silver Staining | 1 | 2004 | 62 | 0.060 |
Why?
|
Verapamil | 1 | 2005 | 242 | 0.060 |
Why?
|
Fluconazole | 1 | 2005 | 154 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1592 | 0.060 |
Why?
|
Cryotherapy | 1 | 2005 | 164 | 0.060 |
Why?
|
West Nile Fever | 1 | 2004 | 77 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1347 | 0.060 |
Why?
|
Sunlight | 1 | 2006 | 336 | 0.060 |
Why?
|
Kidney | 1 | 2019 | 7070 | 0.060 |
Why?
|
Membrane Microdomains | 1 | 2005 | 203 | 0.060 |
Why?
|
Keratin-20 | 1 | 2023 | 31 | 0.060 |
Why?
|
Prednisolone | 1 | 2005 | 324 | 0.060 |
Why?
|
Cysts | 1 | 2009 | 685 | 0.060 |
Why?
|
Leprosy | 1 | 2004 | 125 | 0.060 |
Why?
|
Injections, Intravenous | 1 | 2006 | 1376 | 0.060 |
Why?
|
Communicable Diseases | 1 | 2012 | 873 | 0.050 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 17070 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2016 | 5125 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8524 | 0.050 |
Why?
|
Calcitriol | 1 | 2005 | 299 | 0.050 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2003 | 127 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2001 | 5454 | 0.050 |
Why?
|
Penicillins | 1 | 2006 | 403 | 0.050 |
Why?
|
Endoscopy, Digestive System | 1 | 2005 | 358 | 0.050 |
Why?
|
Pancreatic Polypeptide | 1 | 2002 | 35 | 0.050 |
Why?
|
Gastrins | 1 | 2002 | 75 | 0.050 |
Why?
|
Crohn Disease | 2 | 2016 | 2281 | 0.050 |
Why?
|
Carcinoma, Embryonal | 1 | 2002 | 36 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2018 | 15882 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2024 | 2038 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20698 | 0.050 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2005 | 539 | 0.050 |
Why?
|
Myenteric Plexus | 1 | 2002 | 49 | 0.050 |
Why?
|
Cell Division | 2 | 2015 | 4467 | 0.050 |
Why?
|
Rhabdoid Tumor | 1 | 2004 | 209 | 0.050 |
Why?
|
Desmin | 1 | 2002 | 99 | 0.050 |
Why?
|
Thigh | 1 | 2003 | 236 | 0.050 |
Why?
|
Knee | 1 | 2003 | 273 | 0.050 |
Why?
|
gp100 Melanoma Antigen | 1 | 2001 | 37 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6307 | 0.050 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2002 | 55 | 0.050 |
Why?
|
Adenoma, Bile Duct | 1 | 2001 | 29 | 0.050 |
Why?
|
Myoglobin | 1 | 2002 | 157 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2001 | 62 | 0.050 |
Why?
|
DNA | 1 | 2015 | 7192 | 0.050 |
Why?
|
Extracellular Space | 1 | 2003 | 563 | 0.050 |
Why?
|
Infant, Newborn | 4 | 2007 | 26379 | 0.050 |
Why?
|
Melanoma-Specific Antigens | 1 | 2001 | 73 | 0.050 |
Why?
|
Smad4 Protein | 1 | 2002 | 194 | 0.050 |
Why?
|
Cell Lineage | 1 | 2010 | 2574 | 0.050 |
Why?
|
Bone Marrow | 1 | 2012 | 2916 | 0.050 |
Why?
|
Reference Values | 2 | 1999 | 4909 | 0.050 |
Why?
|
Germinoma | 1 | 2002 | 124 | 0.050 |
Why?
|
Administration, Oral | 2 | 2021 | 4016 | 0.050 |
Why?
|
Micromanipulation | 1 | 2001 | 53 | 0.050 |
Why?
|
Lower Extremity | 2 | 2021 | 1216 | 0.050 |
Why?
|
Dominican Republic | 1 | 2021 | 78 | 0.050 |
Why?
|
Tongue Neoplasms | 1 | 2003 | 185 | 0.050 |
Why?
|
Endosonography | 1 | 2005 | 626 | 0.050 |
Why?
|
Betamethasone | 1 | 2021 | 48 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2017 | 5879 | 0.050 |
Why?
|
Thoracic Wall | 1 | 2003 | 197 | 0.050 |
Why?
|
Boston | 2 | 2011 | 9336 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 702 | 0.050 |
Why?
|
Face | 2 | 2004 | 1029 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2001 | 425 | 0.040 |
Why?
|
Metaplasia | 1 | 2001 | 325 | 0.040 |
Why?
|
Cystadenoma, Serous | 1 | 2001 | 99 | 0.040 |
Why?
|
Regression Analysis | 1 | 2010 | 6324 | 0.040 |
Why?
|
Polyps | 1 | 2002 | 200 | 0.040 |
Why?
|
Lymphoma, T-Cell | 1 | 2002 | 308 | 0.040 |
Why?
|
Sarcoma, Synovial | 1 | 2001 | 157 | 0.040 |
Why?
|
Sarcoma, Kaposi | 1 | 2003 | 376 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2005 | 769 | 0.040 |
Why?
|
Glucagon | 1 | 2002 | 533 | 0.040 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2021 | 361 | 0.040 |
Why?
|
Cephalexin | 1 | 2019 | 37 | 0.040 |
Why?
|
Microfluidic Analytical Techniques | 2 | 2017 | 789 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2210 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2012 | 1943 | 0.040 |
Why?
|
Animals | 9 | 2021 | 168775 | 0.040 |
Why?
|
Dissection | 1 | 2001 | 298 | 0.040 |
Why?
|
Facial Paralysis | 1 | 2003 | 346 | 0.040 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1999 | 205 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2001 | 784 | 0.040 |
Why?
|
Vasculitis | 1 | 2003 | 528 | 0.040 |
Why?
|
Extremities | 1 | 2004 | 868 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5334 | 0.040 |
Why?
|
Mycobacterium chelonae | 1 | 2018 | 12 | 0.040 |
Why?
|
Parvoviridae Infections | 1 | 1998 | 39 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2019 | 280 | 0.040 |
Why?
|
Gastric Mucosa | 1 | 2001 | 602 | 0.040 |
Why?
|
Mesenteric Vascular Occlusion | 1 | 1998 | 93 | 0.040 |
Why?
|
Clarithromycin | 1 | 2018 | 87 | 0.040 |
Why?
|
Barrett Esophagus | 1 | 2002 | 494 | 0.040 |
Why?
|
Signal Transduction | 3 | 2024 | 23600 | 0.040 |
Why?
|
Arterioles | 1 | 1998 | 251 | 0.040 |
Why?
|
Skin Absorption | 1 | 2018 | 96 | 0.040 |
Why?
|
Penis | 1 | 2019 | 209 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2017 | 6101 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Urinalysis | 1 | 2019 | 369 | 0.040 |
Why?
|
Fatty Acids | 1 | 2005 | 1806 | 0.040 |
Why?
|
Circumcision, Male | 1 | 2019 | 150 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5388 | 0.030 |
Why?
|
Immunophenotyping | 2 | 2017 | 1865 | 0.030 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2017 | 72 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 3801 | 0.030 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 7473 | 0.030 |
Why?
|
Karyotyping | 1 | 1999 | 1175 | 0.030 |
Why?
|
Leiomyoma | 1 | 2002 | 644 | 0.030 |
Why?
|
Neurilemmoma | 1 | 2002 | 522 | 0.030 |
Why?
|
United States | 3 | 2021 | 72916 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 18076 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
Intestinal Perforation | 1 | 1998 | 254 | 0.030 |
Why?
|
Elbow | 1 | 2017 | 129 | 0.030 |
Why?
|
Blotting, Western | 1 | 2004 | 5019 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2013 | 4904 | 0.030 |
Why?
|
Cytoplasm | 1 | 2001 | 1498 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2002 | 615 | 0.030 |
Why?
|
Phenotype | 3 | 2016 | 16712 | 0.030 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3942 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 328 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 2002 | 800 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 16039 | 0.030 |
Why?
|
Phosphorylation | 1 | 2007 | 8290 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 712 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 684 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2016 | 125 | 0.030 |
Why?
|
Risk Factors | 2 | 2020 | 74838 | 0.030 |
Why?
|
Genetic Markers | 1 | 2001 | 2603 | 0.030 |
Why?
|
Frozen Sections | 1 | 2015 | 152 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 3 | 2012 | 1882 | 0.030 |
Why?
|
Central Nervous System Cysts | 1 | 2014 | 56 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 268 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2015 | 511 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2005 | 2969 | 0.030 |
Why?
|
Epithelium | 1 | 2019 | 1604 | 0.030 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2782 | 0.030 |
Why?
|
Observer Variation | 1 | 2000 | 2611 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2018 | 2269 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2014 | 322 | 0.030 |
Why?
|
Hand | 2 | 2012 | 909 | 0.030 |
Why?
|
Phylogeny | 1 | 2021 | 2838 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3436 | 0.030 |
Why?
|
Ligands | 1 | 2020 | 3274 | 0.030 |
Why?
|
Schizophrenia | 1 | 2012 | 6975 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2653 | 0.030 |
Why?
|
Incidence | 1 | 2011 | 21509 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1466 | 0.030 |
Why?
|
Uterine Neoplasms | 1 | 2002 | 1425 | 0.030 |
Why?
|
Cross Reactions | 1 | 2014 | 825 | 0.030 |
Why?
|
Recurrence | 1 | 2005 | 8494 | 0.030 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2012 | 74 | 0.030 |
Why?
|
Peroxidases | 1 | 2012 | 134 | 0.030 |
Why?
|
Mice | 5 | 2021 | 81821 | 0.030 |
Why?
|
Upper Extremity | 1 | 2018 | 684 | 0.030 |
Why?
|
Cell Movement | 1 | 2024 | 5194 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2015 | 735 | 0.020 |
Why?
|
Base Sequence | 2 | 2014 | 12405 | 0.020 |
Why?
|
Prospective Studies | 1 | 2016 | 54797 | 0.020 |
Why?
|
Abdomen | 1 | 2018 | 1135 | 0.020 |
Why?
|
Remission Induction | 1 | 2017 | 2413 | 0.020 |
Why?
|
Clusterin | 1 | 2011 | 72 | 0.020 |
Why?
|
Brazil | 1 | 2015 | 1248 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1552 | 0.020 |
Why?
|
Triglycerides | 1 | 1998 | 2441 | 0.020 |
Why?
|
Melanoma, Experimental | 1 | 2014 | 555 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2339 | 0.020 |
Why?
|
Melanins | 1 | 2012 | 290 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2001 | 3048 | 0.020 |
Why?
|
Alleles | 1 | 2001 | 6892 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1649 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2002 | 2559 | 0.020 |
Why?
|
Gestational Age | 1 | 1999 | 3616 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2014 | 909 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 886 | 0.020 |
Why?
|
Tamoxifen | 1 | 2014 | 964 | 0.020 |
Why?
|
Cholesterol | 1 | 1998 | 2901 | 0.020 |
Why?
|
Debridement | 1 | 2012 | 494 | 0.020 |
Why?
|
HeLa Cells | 1 | 2015 | 3070 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3610 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3068 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2014 | 1131 | 0.020 |
Why?
|
Cell Separation | 1 | 2014 | 1718 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2717 | 0.020 |
Why?
|
Reference Standards | 1 | 2012 | 1011 | 0.020 |
Why?
|
Gene Silencing | 1 | 2014 | 1505 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1889 | 0.020 |
Why?
|
Swine | 1 | 2018 | 5986 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2076 | 0.020 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2007 | 64 | 0.020 |
Why?
|
Genotype | 2 | 2012 | 13029 | 0.020 |
Why?
|
Weight Loss | 1 | 2018 | 2711 | 0.020 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 787 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3584 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 2 | 2012 | 5695 | 0.020 |
Why?
|
Silver Compounds | 1 | 2005 | 24 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1535 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2352 | 0.020 |
Why?
|
Homeopathy | 1 | 2005 | 30 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 9600 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2001 | 4354 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4746 | 0.020 |
Why?
|
Viscera | 1 | 2005 | 138 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2014 | 22334 | 0.010 |
Why?
|
Leprostatic Agents | 1 | 2004 | 13 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1276 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5365 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 2005 | 384 | 0.010 |
Why?
|
Indoles | 1 | 2012 | 1832 | 0.010 |
Why?
|
Lipids | 1 | 2015 | 3317 | 0.010 |
Why?
|
Clofazimine | 1 | 2004 | 39 | 0.010 |
Why?
|
Dapsone | 1 | 2004 | 55 | 0.010 |
Why?
|
Apoptosis | 1 | 2020 | 9507 | 0.010 |
Why?
|
West Nile virus | 1 | 2004 | 77 | 0.010 |
Why?
|
Hemangioendothelioma | 1 | 2005 | 112 | 0.010 |
Why?
|
Pregnancy, Multiple | 1 | 2005 | 216 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6492 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 5784 | 0.010 |
Why?
|
Reoperation | 1 | 2014 | 4308 | 0.010 |
Why?
|
Sclerosis | 1 | 2004 | 211 | 0.010 |
Why?
|
Twins | 1 | 2005 | 340 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2010 | 2425 | 0.010 |
Why?
|
Genes, T-Cell Receptor gamma | 1 | 2002 | 15 | 0.010 |
Why?
|
Forearm | 1 | 2005 | 426 | 0.010 |
Why?
|
Sulfonamides | 1 | 2012 | 1980 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7425 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2005 | 587 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8062 | 0.010 |
Why?
|
Rifampin | 1 | 2004 | 350 | 0.010 |
Why?
|
Genes, Immunoglobulin | 1 | 2002 | 283 | 0.010 |
Why?
|
Anion Exchange Protein 1, Erythrocyte | 1 | 2002 | 150 | 0.010 |
Why?
|
Pruritus | 1 | 2005 | 376 | 0.010 |
Why?
|
Foot | 1 | 2005 | 576 | 0.010 |
Why?
|
Herpesvirus 8, Human | 1 | 2003 | 254 | 0.010 |
Why?
|
Acute Disease | 1 | 2012 | 7237 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14747 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3529 | 0.010 |
Why?
|
Vimentin | 1 | 2002 | 257 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17597 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 1999 | 3233 | 0.010 |
Why?
|
Antiporters | 1 | 2002 | 275 | 0.010 |
Why?
|
Dermatologic Agents | 1 | 2005 | 314 | 0.010 |
Why?
|
Pregnancy | 2 | 2017 | 30227 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 2227 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6611 | 0.010 |
Why?
|
Hemangioma | 1 | 2005 | 724 | 0.010 |
Why?
|
Ovariectomy | 1 | 2002 | 612 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3617 | 0.010 |
Why?
|
Thalidomide | 1 | 2004 | 886 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 8925 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6544 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10380 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2010 | 3928 | 0.010 |
Why?
|
Hysterectomy | 1 | 2002 | 864 | 0.010 |
Why?
|
Fibrosis | 1 | 2003 | 2073 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12802 | 0.010 |
Why?
|
Cholangiocarcinoma | 1 | 2001 | 577 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26280 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11906 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15820 | 0.010 |
Why?
|
Adipocytes | 1 | 2001 | 1195 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2005 | 3689 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7423 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9446 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36545 | 0.000 |
Why?
|
Inflammation | 1 | 2004 | 10857 | 0.000 |
Why?
|